person · Reporting owner
Salvadori Daniel Gesua Sive
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EVP AND GROUP PRESIDENT | February 27, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 27, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 146,377 |
Ending reported balance
After 2026-03-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-27 · Tax withholding · Disposed 6,615 · Balance 147,262 Row 2 · 2026-03-02 · Sale · Disposed 885 · Balance 146,377 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 01:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 885 | $115.58 | $102,288.30 |
DisclosureSEC source: 0001620564-26-000007 · form4-03042026_010342.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,377 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,615 | $116.26 | $769,059.90 |
DisclosureSEC source: 0001620564-26-000007 · form4-03042026_010342.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,262 Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 89,226 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0001620564-26-000002 · form4-02272026_120229.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,226 Underlying: Common Shares · 89,226 shares Expires 2036-02-23 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 29,742 on February 24, 2027, 29,742 on February 24, 2028, and 29,742 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 21,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001620564-26-000002 · form4-02272026_120229.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,877 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| December 11, 2025 Filed Dec 12, 2025 22:04 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 1,536 | $123.28 | $189,358.08 |
DisclosureSEC source: 0001620564-25-000009 · form4-12122025_101232.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 132,233 Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,462 | $135.87 | $1,149,731.94 |
DisclosureSEC source: 0001415889-25-006789 · form4-03052025_120314.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EVP AND GROUP PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,769 Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 61,580 | $0.00 Strike: $135.42 | $0.00 |
DisclosureSEC source: 0001415889-25-005918 · form4-02272025_110246.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,580 Underlying: Common Shares · 61,580 shares Expires 2035-02-24 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,526 on February 25, 2026, 20,527 on February 25, 2027, and 20,527 on February 25, 2028. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 23:47 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 16,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-005918 · form4-02272025_110246.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,231 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 00:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 23,771 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-25-002584 · form4-02012025_120236.xml · derivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 23,771 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 00:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 23,771 | $128.50 | $3,054,573.50 |
DisclosureSEC source: 0001415889-25-002584 · form4-02012025_120236.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,697 Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 00:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 23,771 | $38.40 | $912,806.40 |
DisclosureSEC source: 0001415889-25-002584 · form4-02012025_120236.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 963 | $118.50 | $114,115.50 |
DisclosureSEC source: 0001415889-24-006417 · form4-03052024_120350.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,697 Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 8,874 | $120.05 | $1,065,323.70 |
DisclosureSEC source: 0001415889-24-006417 · form4-03052024_120350.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,660 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 58,898 | $0.00 Strike: $116.98 | $0.00 |
DisclosureSEC source: 0001415889-24-005109 · form4-02232024_100201.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,898 Underlying: Common Shares · 58,898 shares Expires 2034-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 19,632 on February 21, 2025, 19,633 on February 21, 2026, and 19,633 on February 21, 2027. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:43 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 15,673 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005109 · form4-02232024_100201.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,534 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 00:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,085 | $100.70 | $109,259.50 |
DisclosureSEC source: 0001415889-23-003916 · form4-03032023_120315.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,861 Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:52 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 9,002 | $99.77 | $898,129.54 |
DisclosureSEC source: 0001415889-23-003916 · form4-03032023_120315.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,946 Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 69,803 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003060 · form4-02232023_120209.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,803 Underlying: Common Shares · 69,803 shares Expires 2033-02-16 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 23,267 on February 17, 2024, 23,268 on February 17, 2025, and 23,268 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 23, 2023 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 17,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003060 · form4-02232023_120209.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,948 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 00:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,550 | $118.17 | $183,165.05 |
DisclosureSEC source: 0001415889-22-002200 · form4-03022022_040330.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,248 Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:58 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 10,551 | $122.41 | $1,291,547.91 |
DisclosureSEC source: 0001415889-22-002200 · form4-03022022_040330.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,798 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 111,474 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001744 · form4-02232022_050251.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,474 Underlying: Common Shares · 111,474 shares Expires 2032-02-17 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 37,158 on February 18, 2023, 37,158 on February 18, 2024, and 37,158 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 23,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001744 · form4-02232022_050251.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,349 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 31,229 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001415889-21-006263 · form4-12282021_021241.xml · derivative · entry 5 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,591 Underlying: Common Shares · 31,229 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 23,771 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-006263 · form4-12282021_021241.xml · derivative · entry 4 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,771 Underlying: Common Shares · 23,771 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 58,501 | $140.00 | $8,190,140.00 |
DisclosureSEC source: 0001415889-21-006263 · form4-12282021_021241.xml · nonDerivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,430 Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 31,229 | $44.40 | $1,386,567.60 |
DisclosureSEC source: 0001415889-21-006263 · form4-12282021_021241.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 23,771 | $38.40 | $912,806.40 |
DisclosureSEC source: 0001415889-21-006263 · form4-12282021_021241.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 31,229 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001415889-21-005967 · form4-12152021_031216.xml · derivative · entry 6 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,803 Underlying: Common Shares · 31,229 shares Expires 2027-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 23,771 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-005967 · form4-12152021_031216.xml · derivative · entry 5 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,542 Underlying: Common Shares · 23,771 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 55,000 | $135.00 | $7,425,000.00 |
DisclosureSEC source: 0001415889-21-005967 · form4-12152021_031216.xml · nonDerivative · entry 4 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,931 Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 31,229 | $44.40 | $1,386,567.60 |
DisclosureSEC source: 0001415889-21-005967 · form4-12152021_031216.xml · nonDerivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 23,771 | $38.40 | $912,806.40 |
DisclosureSEC source: 0001415889-21-005967 · form4-12152021_031216.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 23:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 3,499 | $135.00 | $472,365.00 |
DisclosureSEC source: 0001415889-21-005967 · form4-12152021_031216.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,931 Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 00:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,664 | $120.61 | $200,695.04 |
DisclosureSEC source: 0001415889-21-001212 · form4-03022021_040302.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,430 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:54 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 12,596 | $121.58 | $1,531,421.68 |
DisclosureSEC source: 0001415889-21-001212 · form4-03022021_040302.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,094 Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 98,708 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000899 · form4-02232021_040224.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,708 Underlying: Common Shares · 98,708 shares Expires 2031-02-18 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,902 on February 19, 2022, 32,903 on February 19, 2023, and 32,903 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000899 · form4-02232021_040224.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,690 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 22:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 42,479 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001179110-20-009447 · edgar.xml · derivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 42,479 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 22:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 42,479 | $111.86 | $4,751,700.94 |
DisclosureSEC source: 0001179110-20-009447 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,433 Read SEC document |
| August 27, 2020 Filed Aug 31, 2020 22:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 42,479 | $47.00 | $1,996,513.00 |
DisclosureSEC source: 0001179110-20-009447 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,060 | $99.08 | $105,024.80 |
DisclosureSEC source: 0001179110-20-008463 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,433 Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 999 | $77.89 | $77,812.11 |
DisclosureSEC source: 0001179110-20-002895 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,493 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:16 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 12,279 | $79.19 | $972,374.01 |
DisclosureSEC source: 0001179110-20-002895 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,492 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOptions (right to buy) · Derivative | 132,182 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002286 · edgar.xml · derivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,182 Underlying: Common shares · 132,182 shares Expires 2030-02-20 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 44,060 on February 21, 2021, 44,061 on February 21, 2022, and 44,061 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:32 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 21,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002286 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,771 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| July 21, 2019 Filed Jul 23, 2019 22:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,060 | $87.49 | $92,739.40 |
DisclosureSEC source: 0001179110-19-008773 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,088 Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 71,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-19-008174 · edgar.xml · derivative · entry 3 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,313 Underlying: Common shares · 71,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 71,000 | $84.00 | $5,964,007.10 |
DisclosureSEC source: 0001179110-19-008174 · edgar.xml · nonDerivative · entry 2 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,148 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.00 to $84.04, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 21:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 71,000 | $38.40 | $2,726,400.00 |
DisclosureSEC source: 0001179110-19-008174 · edgar.xml · nonDerivative · entry 1 Salvadori Daniel Gesua Sive · CIK 0001620564 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.